Industry Detail

Market Outline:

Obesity has been categorized into different types, its classification varies depending upon the country guidelines and regional diagnosis. 

Disease Burden Analysis:

• Nearly 700-800 Million people suffering from Obesity globally. Due to substantial change in life style modification, one in every three person is suffering from obesity as per recent statistics
• According to WHO it is estimated that, by 2030 it is predicted that 1 in 5 women and 1 in 7 men will be living with obesity (BMI ≥30kg/m2 ), equating to over 1 billion people globally.
• Global prevalence of obesity is higher amongst women than men, highlighting the need for inclusive policies based on lived experience.
• Over half of the population in OECD countries is overweight, with nearly 1 in 4 people considered obese. In the next 30 years, this will cause 220 million cases of noncommunicable diseases (NCDs) in OECD countries.

Report Insights:

• More than 1500 clinical trials, United States is the dominated region
• Huge unmet need exists
• Gaps in Country Policies Identified ate every level 
• >40 pipeline assets about to witness the market by 2040
• Opportunity worth of USD 70 billion is expected to roll out in the market
• The World Obesity Atlas estimates that the total costs attached to obesity – both healthcare and productivity related – will exceed $4 trillion worldwide by 2035
• Market largely dominated by off-label drugs, Report has analyze the key drugs penetrating as off-label.
• CSP Analytics Solutions provided the clinical mapping of key pipeline molecules

The 9MM Obesity Drug Treatment Market is expected to offer an $ opportunity of USD 1,345 Million over the analysis period. Market was estimated USD XX Million during estimated year i.e. 2023 and expected to grow at a significant CAGR 6.21% over the projected period. And by 2033, the market is expected to touch USD XX Million.

Market Segmentation Analysis by:

• By Treatment Mode:
  • Prescription
  • Off-Label
• By Therapy:
  • Saxenda (liraglutide)
  • Victoza (liraglutide)
  • Liraglutide biosimilar
  • Wegovy (semaglutide)
  • Ozempic (semaglutide) 
  • Others
• By End User:
  • Hospitals
  • Clinics
  • Others

Market Enabler: Explored in report

• Surging Prevalence of Obesity Across Region
• Growing Clinical Trial Activities 
• Huge Market Unmet Need
• Rising drug Penetration in Obesity Segment

Market Challenges: Explored in report

• Lack of Efficacious Treatment Option
• Cost of Treatment
• Off-Label Drug Usages
• Underdiagnoses in Emerging Market
• Substitution of Products

Regional Outlook: 

Report has fragmented the total market in five regions such as US, 5-Europe, China, Japan, India and RoW (Rest of world). 

Each mapped region has been examined at granular level based on certain parameters:

• United States Obesity Drug Treatment Market Assessment
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL)
  • Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
  • Current Policies
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Reimbursement of Drugs
  • Market Unmet Need Analysis
  • Pipeline Drugs in the Region
  • Key Players in the Market and their Market share (%)
• 5-Europe Obesity Drug Treatment Market Assessment
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL)
  • Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
  • Current Policies
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Reimbursement of Drugs
  • Market Unmet Need Analysis
  • Pipeline Drugs in the Region
  • Key Players in the Market and their Market share (%)
• China Obesity Drug Treatment Market Assessment
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL)
  • Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
  • Current Policies
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Reimbursement of Drugs
  • Market Unmet Need Analysis
  • Pipeline Drugs in the Region
  • Key Players in the Market and their Market share (%)
• India Obesity Drug Treatment Market Assessment
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL)
  • Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
  • Current Policies
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Reimbursement of Drugs
  • Market Unmet Need Analysis
  • Pipeline Drugs in the Region
  • Key Players in the Market and their Market share (%)
• Japan Obesity Drug Treatment Market Assessment
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL)
  • Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
  • Current Policies
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Reimbursement of Drugs
  • Market Unmet Need Analysis
  • Pipeline Drugs in the Region
  • Key Players in the Market and their Market share (%)
• Rest of the World Obesity Drug Treatment Market Assessment
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL)
  • Disease Burden Analysis (Prevalence, Diagnosed, Prevalent Pool Analysis)
  • Current Policies
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Reimbursement of Drugs
  • Market Unmet Need Analysis
  • Pipeline Drugs in the Region
  • Key Players in the Market and their Market share (%)

Competitive Landscape: Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.

Companies Profile:

• Eli Lilly
• Novo Nordisk
• Pfizer
• Boehringer Ingelheim
• Zealand Pharma
• OPKO Health
• Versanis Bio Inc.
• Rhythm Pharmaceuticals
• Roche
• Orexigen Therapeutics
• H2-Pharma
• Chelapharm
• Vivus Inc.
• Aphaia Pharma US LLC
• Currax Pharmaceuticals
• NGM Biopharmaceuticals, Inc
• Guangdong Raynovent Biotech Co., Ltd
• Rhythm Pharmaceuticals, Inc.
• FUJIFILM Toyama Chemical Co Ltd
• Others

Pipeline molecules investigated in the report: